Alibaba Health and Novartis reach a digital chronic disease cooperation agreement, jointly building a new model for outpatient management of chronic urticaria.

On March 25, it was reported that Alibaba Health and Novartis Pharmaceuticals have announced a digital chronic disease cooperation in the field of chronic spontaneous urticaria. The two parties will focus on Novartis' global first oral targeted drug for chronic urticaria, rupatadine tablets, and leverage Alibaba Health's digital platform capabilities to provide integrated services from disease popularization, medication guidance to whole-cycle health management. Alibaba Health, relying on its long-term cultivation of the "whole-cycle chronic disease management system," aims to create an "out-of-hospital second consultation room" for patients.